Six-year clinical outcomes of first-generation drug-eluting stents

Tarantini, Giuseppe; Barioli, Alberto; Facchin, Michela; Frigo, Anna Chiara; Napodano, Massimo; Buja, Paolo; D’Amico, Gianpiero; Iliceto, Sabino; Isabella, Giambattista

doi:10.1097/mca.0b013e328362b2ab

Cited by 3 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…al. 101 there were a difference observed between paclitaxel eluting stents and sirolimus eluting stents. The same was true when sirolimus and paclitaxel eluting stents were compared to bare metal stents.…”

Section: Special Reference Tomentioning

confidence: 86%

Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature

Hohenforst-Schmidt¹,

Zarogoulidis²,

Pitsiou³

et al. 2016

J. Cancer

View full text Add to dashboard Cite

Lung cancer being the most prevalent malignancy in men and the 3rd most frequent in women is still associated with dismal prognosis due to advanced disease at the time of diagnosis. Novel targeted therapies are already on the market and several others are under investigation. However non-specific cytotoxic agents still remain the cornerstone of treatment for many patients. Central airways stenosis or obstruction may often complicate and decrease quality of life and survival of these patients. Interventional pulmonology modalities (mainly debulking and stent placement) can alleviate symptoms related to airways stenosis and improve the quality of life of patients. Mitomycin C and sirolimus have been observed to assist a successful stent placement by reducing granuloma tissue formation. Additionally, these drugs enhance the normal tissue ability against cancer cell infiltration. In this mini review we will concentrate on mitomycin C and sirolimus and their use in stent placement.

show abstract

Section: Special Reference Tomentioning

confidence: 86%

Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature

Hohenforst-Schmidt¹,

Zarogoulidis²,

Pitsiou³

et al. 2016

J. Cancer

View full text Add to dashboard Cite

show abstract

“…Target lesion revascularization was 83.6% PES versus 82% EES ( p =0.60) and the 3 year death and infarction survival rates were 86.1% for PES and 87.3% for EES ( p =0.50). Six year long term follow-up was also investigated for PES and SES and no significant differences were observed for MACE between the two stent types ( p =0.52) and TLR ( p =0.68) [88]. Additionally, it was observed that the stent type was not a predictive factor for MACE ( p =0.87) or TLR ( p =0.38).…”

Section: Paclitaxelmentioning

confidence: 99%

Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis

Darwiche

Tsakiridis²,

Teschler

et al. 2013

J Mol Genet Med

View full text Add to dashboard Cite

Tracheal stenosis due to either benign or malignant disease is a situation that the pulmonary physicians and thoracic surgeons have to cope in their everyday clinical practice. In the case where tracheal stenosis is caused due to malignancy mini-interventional interventions with laser, apc, cryoprobe, balloon dilation or with combination of more than one equipment and technique can be used. On the other hand, in the case of a benign disease such as; tracheomalacia the clinician can immediately upon diagnosis proceed to the stent placement. In both situations however; it has been observed that the stents induce formation of granuloma tissue in both or one end of the stent. Therefore a frequent evaluation of the patient is necessary, taking also into account the nature of the primary disease. Evaluation methodologies identifying different types and extent of the trachea stenosis have been previously published. However; we still do not have an effective adjuvant therapy to prevent granuloma tissue formation or prolong already treated granuloma lesions. There have been proposed many mechanisms which induce the abnormal growth of the local tissue, such as; local pressure, local stress, inflammation and vascular endothelial growth factor overexpression. Immunomodulatory agents inhibiting the mTOR pathway are capable of inhibiting the inflammatory cascade locally. In the current mini-review we will try to present the current knowledge of drug eluting stents inhibiting the mTOR pathway and propose a future application of these stents as a local anti-proliferative treatment.

show abstract

“…Migration of vascular smooth muscle cells (SMCs) to the intimal space of blood vessels is a major cause of restenosis . Paclitaxel (PTX), one of the antiproliferative drugs discovered in the past few decades, is routinely prescribed to prevent restenosis in patients with CVD who have undergone surgical procedures. , Previous studies have shown that antiproliferative agents, such as PTX and sirolimus, could reduce SMC proliferation and the risk of restenosis.…”

Section: Introductionmentioning

confidence: 99%

Bilayered Nanoparticles with Sequential Release of VEGF Gene and Paclitaxel for Restenosis Inhibition in Atherosclerosis

Zhu¹,

Xie

Liang³

et al. 2017

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Complete reendothelialization followed by inhibition of smooth muscle cell (SMC) proliferation is considered as an effective therapeutic option to prevent restenosis. We have designed poly(lactide-co-glycolide)-loaded bilayered nanoparticles (NPs) with the ability to sequentially release vascular endothelial growth factor (VEGF)-encoding plasmids from the outer layer and paclitaxel (PTX) from the core to promote endothelial regeneration as well as prevent restenosis. Comparing with conventional NPs, which release VEGF plasmid and PTX simultaneously, we expect that the bilayered NPs could release the VEGF plasmid more rapidly, followed by a delayed release of PTX, resulting in an efficient VEGF gene transfection, which ideally could promote reendothelialization and inhibit excessive SMC growth. Indeed, in the present study, we have observed efficient gene transfection using a model plasmid as well as cell growth attenuation in vitro using Chinese hamster ovary cells. Therapeutic efficacy of the bilayered NPs on restenosis was further evaluated in vivo using a rabbit model of atherosclerosis. The bilayered NPs were administered locally via balloon angioplasty to the injured aortic wall through perfusion. Twenty-eight days after the NP administration, rabbits treated with the bilayered NPs exhibited rapid reendothelialization and inhibition of restenosis, as demonstrated by histological analysis. Increased level of VEGF and decreased level of C-reactive protein, a biological marker that is closely related to atherosclerosis, were also observed from animals treated with the bilayered NPs, implicating ameliorated atherosclerosis. Our results suggest that the VEGF plasmid-/PTX-loaded bilayered NPs exert a beneficial impact on atherosclerotic restenosis by sequentially releasing VEGF and PTX in vivo.

show abstract

Six-year clinical outcomes of first-generation drug-eluting stents

Cited by 3 publications

References 24 publications

Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature

Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature

Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis

Bilayered Nanoparticles with Sequential Release of VEGF Gene and Paclitaxel for Restenosis Inhibition in Atherosclerosis

Contact Info

Product

Resources

About